ClinicalTrials.gg

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Program

RSV vaccine formulation 1 dose

Also written as “RSV vaccine formulation 2 dose”, “RSV vaccine formulation 3 dose” and “RSV vaccine formulation 4 dose”.

Its studies are mostly in Respiratory Syncytial Virus Infections, led by Sanofi.

Furthest: phase 2, since Jul 27, 20202 company-led studies, 0 open or running

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Sanofi20 open or runningphase 2since Jul 27, 2020Jul 27, 2020none ahead

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Jul 27, 2020First study: phase 2 study in Respiratory Syncytial Virus InfectionsFirst studyNCT04491877 · 259 enrolled · United States, Chile, Honduras
  2. Jul 8, 2025Phase 1 study in Respiratory Syncytial Virus InfectionsNCT07071558 · 240 enrolled · Australia

TargetBeta

A vaccine: it acts on a pathogen, not a human gene.

“RSV vaccine formulation 1 dose”name, by rule

Studies

All 2 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT07071558Respiratory Syncytial Virus Infections · Australia1CompletedMar 17, 2026240
NCT04491877Respiratory Syncytial Virus Infections · United States, Chile, Honduras2CompletedApr 13, 2023259

How it is read

Names in the registry

  • “RSV vaccine formulation 1 dose”, 1 entry
  • “RSV vaccine formulation 2 dose”, 1 entry
  • “RSV vaccine formulation 3 dose”, 1 entry
  • “RSV vaccine formulation 4 dose”, 1 entry
  • “RSV vaccine formulation 5 dose”, 1 entry

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.